Bipartite Heterogeneous Network Method Based on Co-neighbor for MiRNA-Disease Association Prediction

In recent years, miRNA variation and dysregulation have been found to be closely related to human tumors, and identifying miRNA-disease associations is helpful for understanding the mechanisms of disease or tumor development and is greatly significant for the prognosis, diagnosis, and treatment of human diseases. This article proposes a Bipartite Heterogeneous network link prediction method based on co-neighbor to predict miRNA-disease association (BHCN). According to the structural characteristics of the bipartite network, the concept of bipartite network co-neighbors is proposed, and the co-neighbors were used to represent the probability of association between disease and miRNA. To predict the isolated diseases and the new miRNA based on the association probability expressed by co-neighbors, we utilized the similarity between disease nodes and the similarity between miRNA nodes in heterogeneous networks to represent the association probability between disease and miRNA. The model's predictive performance was evaluated by the leave-one-out cross validation (LOOCV) on different datasets. The AUC value of BHCN on the gold benchmark dataset was 0.7973, and the AUC obtained on the prediction dataset was 0.9349, which was better than that of the classic global algorithm. In this case study, we conducted predictive studies on breast neoplasms and colon neoplasms. Most of the top 50 predicted results were confirmed by three databases, namely, HMDD, miR2disease, and dbDEMC, with accuracy rates of 96 and 82%. In addition, BHCN can be used for predicting isolated diseases (without any known associated diseases) and new miRNAs (without any known associated miRNAs). In the isolated disease case study, the top 50 of breast neoplasm and colon neoplasm potentials associated with miRNAs predicted an accuracy of 100 and 96%, respectively, thereby demonstrating the favorable predictive power of BHCN for potentially relevant miRNAs.